• BTB Domain Missense Variants in ZBTB24 Cause ICF2 via Protei

  2026-06-19

  This study establishes that missense substitutions in the BTB domain of ZBTB24 can cause immunodeficiency, centromeric instability, and facial anomalies type 2 (ICF2) syndrome by destabilizing the protein, extending the spectrum of pathogenic ZBTB24 variants beyond the zinc finger domain. The findings have direct implications for molecular diagnosis, mechanistic understanding, and future research in epigenetic disorders involving DNA methylation.

• InstaBlue Protein Stain Solution: Fast Coomassie Staining Pr

  2026-06-19

  InstaBlue Protein Stain Solution offers rapid, fixation-free staining for protein bands in polyacrylamide gels, eliminating the need for toxic solvents or extended processing. Best suited for workflows requiring high sensitivity and mass spectrometry compatibility, it is not intended for workflows demanding permanent archival of gels or for use with non-polyacrylamide matrices.

• Ciclesonide for Asthma Research: Protocols, Innovations, and

  2026-06-18

  Ciclesonide’s rapid prodrug activation and high glucocorticoid receptor selectivity make it a gold-standard tool for asthma and allergic rhinitis research. This article unpacks advanced workflows, troubleshooting, and the latest ERAD-hijacking strategies, empowering scientists to leverage APExBIO’s Ciclesonide for reproducible, next-generation respiratory models.

• Biotransformation Pathways of Sulfamonomethoxine in Granular

  2026-06-18

  This study elucidates the mechanisms governing the biotransformation of Sulfamonomethoxine (SMM) in aerobic granular sludge systems. The findings reveal the predominance of biodegradation—especially hydroxylamine-mediated pathways—over adsorption, providing new insights into antibiotic removal in wastewater treatment and environmental risk mitigation.

• Sulfamonomethoxine: Mechanistic Leverage for Translational R

  2026-06-17

  This article offers translational researchers a strategic, mechanistic perspective on Sulfamonomethoxine (SMM)—a dihydropteroate synthase inhibitor—highlighting its pivotal role as both a tool and model for optimizing antibiotic stewardship in veterinary and aquaculture contexts. Drawing on recent environmental and pharmacokinetic insights, we connect molecular action to practical protocol recommendations and chart emerging trends for responsible deployment and environmental risk assessment.

• Ionophore Toxicity in Animals: Molecular Mechanisms and Vete

  2026-06-17

  The reviewed paper offers a comprehensive evaluation of ionophore toxicity in animals, critically advancing the understanding of both clinical and molecular mechanisms. It synthesizes evidence on how ionophores disrupt cellular ion homeostasis, with special attention to the modulatory effects of antibiotics like Tiamulin—crucial for optimizing veterinary infectious disease management.

• ASB3 E3 Ligase Suppresses Antiviral Immunity via MAVS Degrad

  2026-06-16

  This study uncovers the role of the E3 ligase ASB3 as a negative regulator of antiviral innate immunity, demonstrating that it directly targets MAVS for K48-linked polyubiquitination and proteasomal degradation. These findings clarify how host proteins can suppress type I interferon signaling in response to RNA virus infection, with significant implications for understanding immune evasion by pathogens.

• Sulfamonomethoxine: Applied Workflows in Veterinary & Aquati

  2026-06-16

  Sulfamonomethoxine (SMM) stands out as a broad-spectrum sulfonamide antibiotic, enabling targeted inhibition of bacterial and protozoal folate synthesis in veterinary and aquaculture applications. This guide delivers actionable protocols, troubleshooting insights, and environmental stewardship strategies to maximize SMM's translational impact while safeguarding against resistance and ecological risk.

• Structural Insights into TRPM3 Modulation by Neurosteroids a

  2026-06-15

  This study elucidates the molecular mechanisms by which neurosteroids and anticonvulsants regulate the TRPM3 ion channel, a key player in pain perception and neurodevelopmental disorders. High-resolution cryo-EM structures reveal distinct ligand binding sites, offering a foundation for structure-guided therapeutic development.

• Sulfachloropyridazine: Applied Workflows in Antibacterial Re

  2026-06-15

  Sulfachloropyridazine stands out as a versatile sulfonamide antibacterial agent, enabling detailed analyses of microbial community shifts and enzyme inhibition in infection models. This article provides actionable protocols, advanced applications, and troubleshooting tactics for robust, reproducible results in microbiological and pharmacological research.

• Berberine Hydrochloride: Translational Leverage in Gut-Bone

  2026-06-14

  Explore how Berberine hydrochloride advances gut-bone axis and metabolic disease research, with unique insights into translational workflows and experimental optimization. Discover its distinct mechanisms and latest findings supporting its use in cutting-edge assays.

• Hexa His Tag Peptide: Precision Tool for 6X His Protein Puri

  2026-06-13

  Hexa His tag peptide enables precise, antibody-free elution of His-tagged proteins with minimal contamination, supporting advanced protein purification and interaction analysis. Its high solubility, competitive binding, and compatibility with immunoprecipitation workflows are supported by peer-reviewed and product data.

• Perifosine (KRX-0401): Unraveling Apoptosis and Golgi Stress

  2026-06-12

  Explore how Perifosine (KRX-0401) uniquely modulates apoptosis and Golgi apparatus stress via Akt/mTOR pathway inhibition. This in-depth analysis integrates recent neuroprotection research and advanced protocol parameters for cancer and stress response assays.

• Sulfachloropyridazine: Advanced Mechanisms and Research Work

  2026-06-12

  Explore Sulfachloropyridazine as a sulfonamide antibacterial agent, delving into its unique enzyme inhibition profile, advanced research applications, and assay optimization for microbiological and pharmacological studies.

• Sodium Oxamate: LDH-A Inhibition for Cancer Metabolism Studi

  2026-06-11

  Sodium Oxamate is a validated small-molecule inhibitor of LDH-A, widely used to disrupt glycolytic flux in cancer metabolism research. Its competitive action against pyruvate blocks lactate synthesis and enables exploration of metabolic vulnerabilities in tumor bioenergetics.

450 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page